The Assay Genie Aflibercept ELISA has been especially developed for the quantitative analysis of free Aflibercept in serum and plasma samples. Assay Genies’ Aflibercept ELISA is optimized with Eylea®.

Aflibercept (Eylea®) Qualitative ELISA Kit Test Principle

Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtiter plate coated with the reactant for aflibercept. After incubation, the wells are washed. Then, horseradish peroxidase (HRP) conjugated probe is added and binds to aflibercept captured by the reactant on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The colour developed is proportional to the amount of aflibercept in the sample or standard. Results of samples can be determined directly using the standard curve.

Aflibercept (Eylea®) Qualitative ELISA Kit Product Information

About Aflibercept (Eylea®) Qualitative ELISA Kit

Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Compared to other anti-VEGF drugs like bevacizumab and ranibizumab, aflibercept has a higher binding affinity to VEGF-A.

Assay Genie Aflibercept ELISA products:

Eylea® is a trademark of Regeneron Pharmaceuticals Inc.